3C B Liu, G Z Liu, N.Liu, et al. Radiolabeling morpholinos with90Y, 111In, 188Re and 90mTc. Nuclear Medicine and Biology,2003, 30 (1):207～214.
4S Ho, W Y Lau, T W T Leung, et al. Clinical evaliation of the partition model for estimating radiation doses from yttrium-90 mi crospheres in the treatment of hepatic cancer. European Journal of Nuclear Medicine, 1997,24(3):293～298.
5F I Chou, K C Fang, C Chung, et al. Lipiodol uptake and retention by human hepatoma cells. Nuclear Medicine and Biology, 1995,22(3): 379～386.
6J F Yu, U O Hafeli, M Sands,et al. 90Y -oxine-ethiodol, a po tential radiopharmaceutical for the treatment of liver cancer. Ap plied radiation and isotopes, 2003,58(1):567～573.
2Liu O, Klintman D, Corbasico M, et al. Linomide and antibody-targeted superantigen therapy abolishes formation of liver metastases in mice[J]. Eur Surg Res, 2003,35(6) :457-463.
3Hao HJ, Jiang YO, Zheng YL, et al. Improved stability and yield of Fv targeted superantigen by introducing both linker and disulfide bond into the targeting moiety [ J ]. Biochimie, 2005,87 (8) :661-667.
